Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1976 1
1977 1
1981 2
1982 2
1983 3
1984 3
1987 1
1988 3
1990 1
1991 3
1992 2
1993 3
1994 1
1996 3
1997 6
1998 1
1999 4
2000 8
2001 1
2002 7
2003 9
2004 10
2005 8
2006 8
2007 6
2008 1
2009 4
2010 2
2011 3
2012 6
2013 4
2014 4
2015 6
2016 6
2017 2
2018 3
2019 6
2020 9
2021 14
2022 13
2023 21
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: usami t. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20. Lancet. 2024. PMID: 38521086 Clinical Trial.
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, Harano K, Yamamoto K, Maruko T, Ugai H, Tekin C, Colombo N, Fujiwara K, Hasegawa K, Ushijima K. Nishio S, et al. Among authors: usami t. Cancer Sci. 2022 Nov;113(11):3877-3887. doi: 10.1111/cas.15479. Epub 2022 Sep 15. Cancer Sci. 2022. PMID: 35792064 Free PMC article. Clinical Trial.
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Yonemori K, Fujiwara K, Hasegawa K, Yunokawa M, Ushijima K, Suzuki S, Shikama A, Minobe S, Usami T, Kim JW, Kim BG, Wang PH, Chang TC, Yamamoto K, Han S, McKenzie J, Orlowski RJ, Miura T, Makker V, Man Kim Y. Yonemori K, et al. Among authors: usami t. J Gynecol Oncol. 2024 Mar;35(2):e40. doi: 10.3802/jgo.2024.35.e40. Epub 2024 Jan 19. J Gynecol Oncol. 2024. PMID: 38302725 Free PMC article. Clinical Trial.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejía F, Helpman L, Akıllı H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A, Christiaens M, Petru E, Usami T, Liu P, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: usami t. Lancet. 2024 Oct 5;404(10460):1321-1332. doi: 10.1016/S0140-6736(24)01808-7. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288779 Clinical Trial.
Biogenesis of fibrils requires C-mannosylation of PMEL.
Kawahara R, Usami T, Arakawa S, Kamo H, Suzuki T, Komatsu R, Hara H, Niwa Y, Shimizu E, Dohmae N, Shimizu S, Simizu S. Kawahara R, et al. Among authors: usami t. FEBS J. 2023 Nov;290(22):5373-5394. doi: 10.1111/febs.16927. Epub 2023 Aug 18. FEBS J. 2023. PMID: 37552474
Regional variation in end-stage renal disease.
Usami T, Sato R, Yoshida A, Kimura G. Usami T, et al. Curr Opin Nephrol Hypertens. 2002 May;11(3):343-6. doi: 10.1097/00041552-200205000-00012. Curr Opin Nephrol Hypertens. 2002. PMID: 11981266 Review.
Impact of COVID-19-related stress on methamphetamine users in Japan.
Matsumoto T, Usami T, Yamamoto T, Funada D, Murakami M, Okita K, Shimane T. Matsumoto T, et al. Among authors: usami t. Psychiatry Clin Neurosci. 2021 Apr 19;75(7):236-8. doi: 10.1111/pcn.13220. Online ahead of print. Psychiatry Clin Neurosci. 2021. PMID: 33871894 Free PMC article. No abstract available.
[Hypertensive nephrosclerosis].
Fukuda M, Usami T, Kimura G. Fukuda M, et al. Among authors: usami t. Nihon Rinsho. 2004 Mar;62 Suppl 3:357-62. Nihon Rinsho. 2004. PMID: 15171399 Review. Japanese. No abstract available.
[Renal failure--nephrosclerosis].
Usami T, Kimura G. Usami T, et al. Nihon Rinsho. 2005 Mar;63 Suppl 3:149-54. Nihon Rinsho. 2005. PMID: 15813060 Review. Japanese. No abstract available.
200 results